Replies to post #791 on CardioVascular BioTherapeutics (fka CVBT)

[MarciWilliams]

I think the important thing as far as value is concerned initially is enrolling patients in the trial not finishing the trial. The example that my friend gave me was a company called Avexys who had only treated a handful of patients in their phase 1 trial yet Big Pharma paid over $8 billion dollars cash to take the company over. As I understand it Avexys had 1 patent and 1 therapy which only treated a small number of patients each year. I think this highlights the appetite the big companies have for biotech.

[KalratiInvestor]

Newer Investor Here

Had to respond hapcody because one of the reasons we invested was the potential of this company. It seems that they are targeting many life altering diseases so even if there was a government take over of healthcare, therapies for patients would still be needed. Especially if they are more cost effective treatments.

Second, why would it take two years to get relisted? Would appreciate anyone who could shed some light on this.